Efficacy of afoxolaner in a clinical field study in dogs naturally infested with<i>Sarcoptes scabiei</i>

Beugnet, Frédéric; Vos, Christa de; Liebenberg, Julian; Halos, Lénaïg; Larsen, Diane; Fourie, Josephus J.

doi:10.1051/parasite/2016026

Cited by 45 publications

(41 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In naturally infested dogs (n ϭ 10), Beugnet et al showed that oral AFX dosed at 2.5 mg/kg also achieved a 100% efficacy on the basis of mite counts at D28 and D56 posttreatment. Clinical scores declined to 80% in the AFX-treated dogs versus 50% in the control group (28). The general observations of the present study were strictly comparable to those of our first trial (24) and successfully replicated previous Australian reports (23,32,33) with regard to the development of disease, strengthening the use of this robust experimental model for drug development.…”

Section: Evaluation Of Afoxolaner In a Porcine Scabies Modelsupporting

confidence: 90%

See 1 more Smart Citation

Efficacy and Pharmacokinetics Evaluation of a Single Oral Dose of Afoxolaner against Sarcoptesscabiei in the Porcine Scabies Model for Human Infestation

Bernigaud

Fang

Fischer

et al. 2018

Antimicrob Agents Chemother

Self Cite

View full text Add to dashboard Cite

Scabies is a major and potentially growing public health problem worldwide with an unmet need for acaricidal agents with greater efficacy and improved pharmacological properties for its treatment. The objective of the present study was to assess the efficacy and describe the pharmacokinetics profile of a novel acaricide, afoxolaner (AFX), in a relevant experimental porcine model. Twelve pigs were experimentally infested and either treated with 2.5 mg/kg single dose oral AFX ( = 4) or 0.2 mg/kg, two doses 8 days apart, oral ivermectin ([IVM] = 4) or not treated for scabies ( = 4). The response to treatment was assessed by the reduction of mite counts in skin scrapings as well as clinical and pruritus scores over time. Plasma and skin pharmacokinetics profiles for both AFX and IVM were evaluated. AFX efficacy was 100% at days 8 and 14 posttreatment and remained unchanged until the study end (day 45). IVM efficacy was 86% and 97% on days 8 and 14, respectively, with a few mites recovered at the study end. Clinical and pruritus scores decreased in both treated groups and remained constant in the control group. Plasma mean residence times (MRT) were 7.1 ± 2.4 and 1.1 ± 0.2 days for AFX and IVM, respectively. Skin MRT values were 16.2 ± 16.9 and 2.7 ± 0.5 days for AFX and IVM, respectively. Overall, a single oral dose of AFX was efficacious for the treatment of scabies in experimentally infested pigs and showed remarkably long MRTs in plasma and, notably, in the skin.

show abstract

Section: Evaluation Of Afoxolaner In a Porcine Scabies Modelsupporting

confidence: 90%

“…In fact, one pig of three was still infested with live mites at the end of the study. Laboratory or field studies looking at the efficacy of AFX (28) or other isoxazolines such as fluralaner or sarolaner (29-31) against S. scabiei…”

Section: Discussionmentioning

confidence: 99%

Efficacy and Pharmacokinetics Evaluation of a Single Oral Dose of Afoxolaner against Sarcoptesscabiei in the Porcine Scabies Model for Human Infestation

Bernigaud

Fang

Fischer

et al. 2018

Antimicrob Agents Chemother

Self Cite

View full text Add to dashboard Cite

show abstract

“…The present study demonstrates that treatment with a single oral dose (at or approaching the minimum recommended dosage of 2.5 mg/kg) of afoxolaner (NexGard® Chewables) resulted in a rapid reduction in ear mite numbers, suggesting that a single oral administration of NexGard is highly effective (> 98%) against O. cynotis infestations in dogs, as assessed 28 days post-administration. This is comparable to efficacy achieved when afoxolaner was tested against other mite species infesting dogs, namely Sarcoptes scabiei (100% efficacy based on mite counts) [12] and Demodex spp., with > 99% efficacy based on mite counts in a well-controlled study [12] and resolution of cases under field conditions [14]. …”

Section: Discussionsupporting

confidence: 52%

“…It is administered at a minimum dose of 2.5 mg/kg, and comparative studies have shown that monthly administrations of afoxolaner provide outstanding protection against fleas and ticks [10, 11]. Afoxolaner has also demonstrated to be highly efficacious against Sarcoptes scabiei [12] and Demodex canis [13, 14]. Based on these observations, the present study was undertaken to assess the efficacy of a single oral administration of afoxolaner (NexGard) against O. cynotis infestations in dogs.…”

Section: Introductionmentioning

confidence: 99%

Assessment of afoxolaner efficacy against Otodectes cynotis infestations of dogs

Carithers¹,

Crawford²,

Vos

et al. 2016

Parasites Vectors

Self Cite

View full text Add to dashboard Cite

BackgroundThe efficacy of a single 2.5 mg/kg dose of afoxolaner (NexGard®, Merial) against induced Otodectes cynotis infestations was assessed in eight afoxolaner-treated dogs, compared to eight untreated dogs.MethodsAfter O. cynotis infestations were established and confirmed by otoscopic assessments in 16 dogs, all of the dogs were included in the study and allocated to two separate treatment groups. The first group of eight ear mite-infested dogs remained untreated, while afoxolaner was administered orally to the second group of dogs at the minimum recommended dose once on Day 0. Otoscopic assessments performed on all dogs (Days -7, -2, 14 and 28) confirmed the presence or absence of live mites throughout the study. No serious adverse events were recorded throughout the study, and no adverse events were likely related to the administration of NexGard.ResultsBy Day 28, seven out of eight untreated dogs were still infested with ear mites, while only two out of eight afoxolaner-treated dogs were infested, with one and four ear mites, respectively. On Day 28, the reductions of mite counts in the afoxolaner-treated group versus those of the control dogs were 98.5% based on geometric means, and 99.4% based on arithmetic means. Significantly fewer (P < 0.05) live mites were present in the afoxolaner-treated group than the untreated group on Day 28.ConclusionThe results of this study demonstrated that a single oral administration of afoxolaner at the minimum recommended dose is highly effective (>98%) in treating dogs with induced O. cynotis infestations.

show abstract

“…Afoxolaner (NexGard ® , Merial; Lyon, France) is an antiparasitic drug in the class of isoxazolines . The mechanism of action of the isoxazolines is inhibition of chloride channels dependent on glutamate and gamma‐aminobutyric acid (GABA) .…”

Section: Introductionmentioning

confidence: 99%

Effect of oral afoxolaner on naturally occurring infestations of peacocks by the louse Goniodes pavonis

Yarto-Jaramillo¹,

Marquez

Díaz

et al. 2018

Veterinary Dermatology

View full text Add to dashboard Cite

Background -Ectoparasitism of ornamental birds, including captive species kept in zoos, represents a serious health problem. Up to 13 different species of lice have been reported to affect peacocks worldwide and heavy infestation may cause anaemia. Because of this, alternatives to the prevailing treatments have been sought including use of isoxazolines. This class of drugs has been used successfully in poultry without adverse effects on health or production.Objective -To evaluate the effect of afoxolaner on the peacock louse (Goniodes pavonis).Animals -Twenty-three peacocks (Pavo cristatus) with naturally occurring infestation with G. pavonis.Methods and materials -The peacocks were divided in two groups; one was treated once orally with 2.5 mg/kg afoxolaner and the other group received no treatment. Samples were collected using the acetate tape technique, for identification of lice by microscopy. Concomitantly, blood samples were taken to evaluate the haematocrit before and after the intervention.Results -Treatment with afoxolaner significantly decreased the number of peacocks positive for lice (P = 0.02) compared to the control group, in which the number of positive birds did not decrease. The haematocrit improved in the afoxolaner-treated group from a baseline of 46.4%-54.7% at 35 days post-treatment, whereas it decreased in untreated birds (44.6%-40.7%). No adverse effects attributed to afoxolaner treatment were observed.Conclusions and clinical importance -Oral administration of afoxolaner is an effective treatment for G. pavonis infestation of peacocks. AnimalsGoniodes pavonis lice were collected from 23 peacocks, which were transferred to the Parasitology and Microbiology laboratory of the

show abstract

Efficacy of afoxolaner in a clinical field study in dogs naturally infested withSarcoptes scabiei

Cited by 45 publications

References 18 publications

Efficacy and Pharmacokinetics Evaluation of a Single Oral Dose of Afoxolaner against Sarcoptesscabiei in the Porcine Scabies Model for Human Infestation

Efficacy and Pharmacokinetics Evaluation of a Single Oral Dose of Afoxolaner against Sarcoptesscabiei in the Porcine Scabies Model for Human Infestation

Assessment of afoxolaner efficacy against Otodectes cynotis infestations of dogs

Effect of oral afoxolaner on naturally occurring infestations of peacocks by the louse Goniodes pavonis

Contact Info

Product

Resources

About